Actively Recruiting

Phase 2
Age: 18Years +
All Genders
NCT06482086

Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer

Led by West China Hospital · Updated on 2024-12-05

75

Participants Needed

1

Research Sites

234 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The current study aims to explore the potential advantages of anti-cancer therapy that is implemented based on drug sensitivity testing. This pertains to individuals with locally advanced thyroid cancer who have undergone conventional therapy in the past or unresectable patients .

CONDITIONS

Official Title

Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adult participants initially diagnosed with locally advanced thyroid cancer or with persistent or recurrent thyroid cancer, including cervical nodal recurrence
  • Diagnosis includes papillary, follicular, medullary, poorly differentiated, or anaplastic thyroid carcinoma
  • Evidence of tumor extension beyond the thyroid or locally invasive disease considered at risk for incomplete surgical removal
  • At least one measurable tumor lesion according to modified response criteria
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
  • Normal organ and bone marrow function
  • Adequate organ function including bone marrow, coagulation, kidney, liver, and heart within 28 days before registration
  • Ability to swallow pills
  • Signed informed consent form
  • Expected survival time longer than 2 months
Not Eligible

You will not qualify if you...

  • Contraindications to the targeted drugs used in organoid drug sensitivity tests
  • Incomplete clinical data
  • Severe organ dysfunction, metabolic diseases, or other conditions greatly affecting survival
  • Other active malignant diseases requiring treatment
  • Pregnancy or breastfeeding
  • Absence of target tumor lesions
  • Deemed unsuitable for inclusion by the researchers

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

West China hospital

Chengdu, Sichuan, China, 610041

Actively Recruiting

Loading map...

Research Team

Z

Zhihui Li, Professor

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here